Kimberly Lynn Blackwell, MD

Adjunct Professor in the Department of Medicine
Campus mail Duke Box 3893, Durham, NC 27710
Phone (919) 668-1748
Email address black034@mc.duke.edu

Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1997 - 2000
  • Medical Resident, Medicine, Duke University, 1994 - 1997
  • M.D., Mayo School of Health Sciences, 1994

Publications

Sammons, Sarah, Noah S. Kornblum, and Kimberly L. Blackwell. “Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer.” Target Oncol 14, no. 1 (February 2019): 1–12. https://doi.org/10.1007/s11523-018-0587-9.

PMID
30136059
Full Text

Sammons, Sarah, Noah S. Kornblum, and Kimberly L. Blackwell. “Correction to: Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer.” Target Oncol 14, no. 1 (February 2019): 13. https://doi.org/10.1007/s11523-018-0614-x.

PMID
30535552
Full Text

Force, Jeremy, Lynn J. Howie, Sara E. Abbott, Rex Bentley, P Kelly Marcom, Gretchen Kimmick, Kelly Westbrook, et al. “Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype.” Clin Breast Cancer 18, no. 5 (October 2018): 410–17. https://doi.org/10.1016/j.clbc.2018.02.010.

PMID
29615305
Full Text

Bardia, Aditya, Ayca Gucalp, Noashir DaCosta, Nashat Gabrail, Michael Danso, Haythem Ali, Kimberly L. Blackwell, et al. “Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.” Breast Cancer Res Treat 171, no. 1 (August 2018): 111–20. https://doi.org/10.1007/s10549-018-4813-z.

PMID
29744674
Full Text

Hortobagyi, G. N., S. M. Stemmer, H. A. Burris, Y. S. Yap, G. S. Sonke, S. Paluch-Shimon, M. Campone, et al. “Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.” Ann Oncol 29, no. 7 (July 1, 2018): 1541–47. https://doi.org/10.1093/annonc/mdy155.

PMID
29718092
Full Text

Argento, A Christine, Daniel L. Gilstrap, Scott Shofer, Kamran Mahmood, Kimberly Blackwell, and Momen M. Wahidi. “Endobronchial Ultrasound-guided Transbronchial Needle Aspiration in the Diagnosis of Breast Cancer Thoracic Metastases and Detection of Receptor Discordance.” J Bronchology Interv Pulmonol 25, no. 3 (July 2018): 176–80. https://doi.org/10.1097/LBR.0000000000000476.

PMID
29944588
Full Text

Blackwell, Kimberly, Joseph Gligorov, Ira Jacobs, and Chris Twelves. “The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer.” Clin Breast Cancer 18, no. 2 (April 2018): 95–113. https://doi.org/10.1016/j.clbc.2018.01.006.

PMID
29525430
Full Text

Harbeck, Nadia, Pere Gascón, Andriy Krendyukov, Nadja Hoebel, Sreekanth Gattu, and Kimberly Blackwell. “Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.” Oncologist 23, no. 4 (April 2018): 403–9. https://doi.org/10.1634/theoncologist.2017-0348.

PMID
29317553
Full Text

Blackwell, K., P. Gascon, A. Krendyukov, S. Gattu, Y. Li, and N. Harbeck. “Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.” Ann Oncol 29, no. 1 (January 1, 2018): 244–49. https://doi.org/10.1093/annonc/mdx638.

PMID
29091995
Full Text

Pages